Myeloma Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Myeloma
| Protocol | EAA181 |
|---|---|
| Cancer Type: | Newly diagnosed Multiple Myeloma |
| Fast Facts |
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S2209 |
|---|---|
| Cancer Type: | Mulitple Myloma |
| Fast Facts |
S2209 A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or Single-Agent Maintenance
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAA173 |
|---|---|
| Cancer Type: | Smoldering Myeloma |
| Fast Facts |
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1803 |
|---|---|
| Cancer Type: | Multiple Myeloma |
| Fast Facts |
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
